Perbandingan antara high density lipoprotein, lipoprotein(a) dan small dense low density lipoprotein sebagai parameter pertanda risiko penyakit jantung koroner
Article Sidebar
Main Article Content
Abstract
Penyakit jantung koroner (PJK) merupakan penyebab kematian utama di Indonesia seperti juga di berbagai negara industri di dunia. Aterosklerosis merupakan penyebab utama dari PJK. Faktor risiko utama sebagai penyebab aterosklerosis dan PJK adalah hipertensi, diabetes melitus, dislipidemia, kurang aktifitas dan merokok. Beberapa faktor risiko lainnya adalah high density lipoprotein (HDL) kolesterol (HDL-k), low density lipoprotein (LDL) kolesterol (LDL-k), lipoprotein a [Lp(a)], dan small dense LDL (sd-LDL). Penelitian ini bertujuan untuk membandingkan HDL-k, Lp(a) dan sd-LDL sebagai pertanda risiko terjadinya PJK.
Metode
Subyek penelitian dibagi dalam dua kelompok yaitu kelompok risiko mengikutsertakan 94 subyek yang memiliki minimal 2 faktor risiko PJK dan kelompok kontrol 49 subyek tanpa faktor risiko PJK. Pemeriksaan sampel darah vena dilakukan pada subyek yang sebelumnya telah berpuasa 12–14 jam. Pertanda faktor risiko yang diperiksa adalah HDL-k, Lp(a) dan sd-LDL. Tiga alternatif multivariat model dibandingkan sd-LDL, sd-LDL + HDL-k, dan sd-LDL, HDL-k + Lp(a).
Hasil
Hasil penelitian menunjukkan sd-LDL merupakan pertanda risiko PJK yang akurat. Ternyata Lp(a) dan HDL-k kurang akurat bila digunakan sebagai pertanda risiko PJK dibandingkan dengan sd-LDL.
Kesimpulan
Small dense LDL merupakan pertanda risiko PJK yang akurat. Perlu dilakukan penelitian lebih lanjut dengan mengikut sertakan lebih banyak penderita PJK dan kontrol dengan usia yang sebanding.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
PB. Perkeni. Petunjuk praktis penatalaksanaan dislipidemia. Jakarta: Departemen Ilmu Penyakit Dalam FKUI; 2004.
Kreisberg R, Oberman A. Medical management of hyperlipidemia/ dyslipidemia. J Clin Endocrin Met 2003; 88: 2445-61.
Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004; 109 [suppl III]: III-2-7.
Rizzol M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. Q J Med 2006; 99:1-14.
Tikac I, Kimball BP, Lewis G, Uffelman K, Steiner G. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles. Arterioscler Thromb Vasc Biol 1997; 17: 3633-8.
Yarnell JWG, Patterson CC, Sweetnam PM, Lowe GDO. Haemostatic/inflammatory markers predict 10-year risk of IHD at least as well as lipids: the Caerphilly collaborative studies. Eur Heart J 2004; 25: 1049-56.
Greenberg RS, Daniels SR, Flanders WD, Eley JW, Boring JR III, editors. Diagnostic testing. In: Medical epidemiology. 3rd ed. New York: Lange Medical Books/McGraw-Hill; 2001.
Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, pathophysiology, and therapeutic aspects. Diabetes Metab 1999; 25: 199-211.
Lamarche B, St Pierre AC, Ruel IL, Cantin B, Dagenais GR, Després JP, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 2001; 17: 859–65.
St-Pierre AC, Ruel IL, Cantin B, Dagenais GR, Bernard PM, Depres JP, et al. Comparison of various electrophoretic characteristic of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001; 104: 2295-99.
St-Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard P-M, Després J-P, Lamarche B. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25: 553-9.
Frolkis J. Should one routinely screen for lipoprotein(a)? Cleve Clin J Med 1999; 66: 465-8.
Allan D. How, when and why to use apoplipoprotein B in clinical practice. Am J Cardiol 2002; 17: 48i-54i.
Hirano T, Yoshino G, Adachi M. Doxazosin reduces prevalence of small dense LDL and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens 2001; 14: 908-13.
Pontrelli L, Parris, Adeli K. Atorvastatin treatment beneficially alters the lipoprotein profile and incerase LDL lipoprotein particles diameter in patients with combined dyslipidemia and impaired fasting glucose type 2 diabetes. Metabolism 2002; 51: 334-42.
Yoshino G, Hirano T. Treatment of small dense LDL. J Atheroscler Thromb 2002; 9: 266-75.
Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, et al. Lipoprotein(a) cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999; 45: 1039-46.
Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: meta analysis of prospective studies. Clin Chem 1998; 44: 2301-6.
Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, et al. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163: 377-84.